ClinicalTrials.gg
CompletedNCT01668511Updated Nov 20, 2017

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-981 in Patients With Osteoarthritis of the Knee

A Phase 1 interventional study of ABT-981 and Placebo in Osteoarthritis, sponsored by AbbVie (prior sponsor, Abbott). Completed at 1 site in United States. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-11-20.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,029 studies in Osteoarthritis with a site in United States — 116 open to participants now, 175 under way, 14 of them phase 3. Osteoarthritis · United States.

Enrollment
647th of 832
36 · median 100
Started
2012
with 50 others
Phase 1
45 of 1,029
6 open now
Registered
398th of 1,029
by date

Among the 1,029 studies in Osteoarthritis with a site in United States, this one is the 647th largest by enrollment of the 832 interventional ones that give a count, is one of 51 that started in 2012, is one of 45 in phase 1, and was the 398th registered.

Osteoarthritis

2,975 studies on the registry are indexed under Osteoarthritis; 436 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

116 of the 1,029 studies in Osteoarthritis with a site in United States are open now. Recruiting first, the newest first:

111 more — sign in →

All 116 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 40 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,029 studies in Osteoarthritis with a site in United States, or all of them as a file.
02

Study summary

To assess the safety, tolerability and pharmacokinetics of ABT-981 in patients with osteoarthritis of the knee.

Read the detailed description

This is a phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose study. Thirty-six patients with osteoarthritis of the knee will be selected to participate. Patients will be randomized to receive either ABT-981 or placebo. ABT-981 or placebo will be administered as subcutaneous (under the skin) injections in four dosing groups. Subjects will be administered subcutaneous injections of ABT-981 for up to 8 weeks.

03

Conditions studied

  • Osteoarthritis

Browse trials for

Keywords

  • Immunogenicity
  • Safety
  • Tolerability
  • Osteoarthritis
  • Pharmacokinetics
04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult male or female, 40 to 70 years of age, inclusive.
  • History of symptomatic osteoarthritis (OA) of the knee joint for at least 3 months, with typical Osteoarthritis (OA) symptoms
  • Radiographic Osteoarthritis (OA) of Kellgren-Lawrence (K-L) grade 1, 2 or 3
  • Patients assessment of Osteoarthritis (OA) pain intensity of the study joint is between 40 and 80 on the 0 - 100 mm VAS scale
  • Other than Osteoarthritis (OA) of the study joint, patient should be in general good health

Exclusion criteria

Exclusion Criteria:

  • Radiographic OA of Kellgren-Lawrence grade 4 or chronic opioid user due to severe knee OA
  • History of allergic reaction or significant sensitivity to any constituents of the study drug and acetominophen or history of anaphylactic reaction to any agent
  • Significant trauma or surgery to the study joint within the last year or arthroscopy within 6 months, or, scheduled for major surgery to the study joint
  • Diagnosis of rheumatoid arthritis, other disorders or any arthritis other than Osteoarthritis (OA) of the knee.
  • Any uncontrolled medical illness including unstable treatment or therapy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Group 1

    Randomized 7 drug/2 placebo by group

    Biological: ABT-981 · Biological: Placebo

  • Experimental
    Group 2

    Randomized 7 drug/2 placebo by group

    Biological: ABT-981 · Biological: Placebo

  • Experimental
    Group 3

    Randomized 7 drug/2 placebo by group

    Biological: ABT-981 · Biological: Placebo

  • Experimental
    Group 4

    Randomized 7 drug/2 placebo by group

    Biological: ABT-981 · Biological: Placebo

Interventions

  • BiologicalABT-981

    Injection

  • BiologicalPlacebo

    Placebo Injection

06

What researchers measure

Primary outcomes

  1. Number of participants with Adverse Events

    Collect all adverse events at each visit

    Time frame: From date of first dose of ABT-981 until 70 days after the last dose of ABT-981

  2. Physical Exam including vital signs

    Blood pressure, heart rate and body temperature

    Time frame: From date of first dose of ABT-981 until 70 days after last dose of ABT-981

  3. Clinical Lab Testing

    Hematology, Chemistry, and Urinalysis

    Time frame: From date of first dose of ABT-981 until 70 days after the last dose of ABT-981

  4. Change from Baseline in Electrocardiogram (ECG)

    ECGs done in triplicate

    Time frame: Prior to dose and 8 hours post dose on each day of dosing

  5. Maximum observed serum concentration (Cmax) of ABT-981

    Cmax

    Time frame: Prior to first dose up to 70 days after the last dose of ABT-981

  6. Time to Cmax (Tmax) of ABT-981

    Time to Cmax

    Time frame: Prior to first dose up to 70 days after the last dose of ABT-981

  7. The area under the time curve (AUC) of ABT-981

    AUC

    Time frame: Prior to first dose up until 70 days after the last dose of ABT-981

  8. The terminal phase elimination rate constant and the terminal elimination half-life (t1/2) of ABT-981

    The terminal phase elimination rate constant and the terminal elimination half-life (t1/2) of ABT-981

    Time frame: Prior to the last dose up to 70 days after the last dose of ABT-981

Secondary outcomes

  1. Measurement of anti-drug anti-bodies (ADA) of ABT-981

    Measurement of ADA

    Time frame: Prior to each dose and up until 70 days after the last dose of ABT-981

07

Study locations

1 site
  • Site Reference ID/Investigator# 78613
    Miami, Florida 33136, United States
08

References and documents

Publications

  • Wang SX, Abramson SB, Attur M, Karsdal MA, Preston RA, Lozada CJ, Kosloski MP, Hong F, Jiang P, Saltarelli MJ, Hendrickson BA, Medema JK. Safety, tolerability, and pharmacodynamics of an anti-interleukin-1alpha/beta dual variable domain immunoglobulin in patients with osteoarthritis of the knee: a randomized phase 1 study. Osteoarthritis Cartilage. 2017 Dec;25(12):1952-1961. doi: 10.1016/j.joca.2017.09.007. Epub 2017 Sep 28. PubMed 28964890 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2012
First posted
Aug 20, 2012
Start
Sep 2012
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Last update
Nov 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01668511
Responsible party
Sponsor
First posted
Aug 20, 2012
Start date
Sep 2012
Primary completion
Oct 2013
Completion
Oct 2013
Last update
Nov 20, 2017

Study contacts

Susanne X. Wang, MD
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutikizumab

Start the discussion